Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

被引：0
|
作者：
Rong Shi
Tong Lu
Grace Ku
Hao Ding
Tomohisa Saito
Leonid Gibiansky
Priya Agarwal
Xiaobin Li
Jin Yan Jin
Sandhya Girish
Dale Miles
Chunze Li
Dan Lu
机构：
[1] Genentech Inc.,
[2] Chugai Pharmaceutical Co.,undefined
[3] Ltd.,undefined
[4] QuantPharm LLC,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Ethnic sensitivity assessment; NHL; Non-hodgkin lymphoma; PK; Polatuzumab vedotin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：347 / 359
页数：12
相关论文
共 50 条
  • [11] Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
    Patel, Kishan K.
    Isufi, Iris
    Kothari, Shalin
    Foss, Francine
    Huntington, Scott
    LEUKEMIA & LYMPHOMA, 2020, 61 (14) : 3387 - 3394
  • [12] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
    Amaya, M. L.
    Jimeno, A.
    Kamdar, M.
    DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
  • [13] Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    Cheah, Chan Yoon
    Bartlett, Nancy L.
    Assouline, Sarit
    Schuster, Stephen J.
    Kim, Won Seog
    Shadman, Mazyar
    Isufi, Iris
    Yin, Shen
    Doral, Michelle Y.
    Sit, Jason
    Chen, Vivian
    Huang, Huang
    Zhou, Mingzhu
    Wei, Michael C.
    Budde, L. Elizabeth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S455 - S455
  • [14] Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients
    Song, Yuqin
    Zhang, Qingyuan
    Cai, Qingqing
    Song, Yongping
    Zhang, Liling
    He, Pengcheng
    Wang, Li
    Hirata, Jamie
    Musick, Lisa
    Deng, Rong
    Liu, Wenxin
    Wang, Xin
    Zhu, Jun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2024, 20 (07) : 2133 - 2140
  • [15] Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Makita, Shinichi
    Yamamoto, Go
    Maruyama, Dai
    Asano-Mori, Yuki
    Kaji, Daisuke
    Ananthakrishnan, Revathi
    Ogasawara, Ken
    Stepan, Lara
    Schusterbauer, Claudia
    Rettby, Nils
    Hasskarl, Jens
    Izutsu, Koji
    CANCER MEDICINE, 2022, 11 (24): : 4889 - 4899
  • [16] Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents
    Mato, Sara
    Carita, Lorenzo
    Colmenero, Ariadna
    Andres, Mara
    Balague, Olga
    Andion, Maitane
    Astigarraga, Itziar
    Celis, Veronica
    Mendoza, Carmen
    Guerra-Garcia, Pilar
    Valero, Lorena
    Galera, Ana
    Tallon, Maria
    Pol, Melina
    Castrejon-de-Anta, Natalia
    Frauenfeld, Leonie
    Garcia, Noelia
    Campo, Elias
    Salaverria, Itziar
    Verdu-Amoros, Jaime
    BRITISH JOURNAL OF HAEMATOLOGY, 2025,
  • [17] Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia
    Anoop, Parameswaran
    Sankpal, Sushama
    Stiller, Charles
    Tewari, Sanjay
    Lancaster, Donna L.
    Khabra, Komel
    Taj, Mary M.
    LEUKEMIA & LYMPHOMA, 2012, 53 (10) : 1882 - 1888
  • [18] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
    Saburi, Masuho
    Sakata, Masanori
    Kodama, Yousuke
    Uraisami, Keiichi
    Takata, Hiroyuki
    Miyazaki, Yasuhiko
    Wada, Junpei
    Urabe, Shogo
    Ohtsuka, Eiichi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, : 201 - 204
  • [19] Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma
    Lu, Tong
    Gibiansky, Leonid
    Li, Xiaobin
    Li, Chunze
    Shi, Rong
    Agarwal, Priya
    Hirata, Jamie
    Miles, Dale
    Chanu, Pascal
    Girish, Sandhya
    Jin, Jin Yan
    Lu, Dan
    LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2905 - 2914
  • [20] Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma
    Camus, Vincent
    Tilly, Herve
    FUTURE ONCOLOGY, 2020, 17 (02) : 127 - 136
12345